CoChat

Non-genomic effects of nuclear receptors: insights from the anucleate platelet

Open access
Unsworth, Amanda J, Flora, Gagan D, Gibbins, Jonathan M · 2018 · Cardiovascular Research

The DOI matches its Crossref record; 107 of the 108 references it cites were found in a registry or an index.

Abstract

Nuclear receptors (NRs) have the ability to elicit two different kinds of responses, genomic and non-genomic. Although genomic responses control gene expression by influencing the rate of transcription, non-genomic effects occur rapidly and independently of transcriptional regulation. Due to their anucleate nature and mechanistically well-characterized and rapid responses, platelets provide a model system for the study of any non-genomic effects of the NRs. Several NRs have been found to be present in human platelets, and multiple NR agonists have been shown to elicit anti-platelet effects by a variety of mechanisms. The non-genomic functions of NRs vary, including the regulation of kinase and phosphatase activity, ion channel function, intracellular calcium levels, and production of second messengers. Recently, the characterization of mechanisms and identification of novel binding partners of NRs have further strengthened the prospects of developing their ligands into potential therapeutics that offer cardio-protective properties in addition to their other defined genomic effects.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/cvr/cvy044

Cites

107 of 107 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 LXR and FXR ligands negatively regulate platelet function through inhibition of platelet signalling and formation of procoagulant coated platelets. Treatment of platelets with LXR ligands results in reduced tyrosine phosphorylation of key GPVI signalling molecules Syk, LAT and PLCγ2. An increase in the level of LXR–Syk and LXR–PLCγ2 interaction is also observed. Exposure to LXR ligands also renders platelets into a procoagulant state characterized by the exposure of phosphatidylserine and α-granule contents on the platelet surface, which is coupled with depolarization of the mitochondrial membrane potential, reduced calcium mobilization and down-regulation in the affinity of integrin αIIbβ3, ultimately resulting in the inhibition of platelet aggregation. Similarly, incubation of platelets with FXR ligands can lead to platelet swelling and conversion to procoagulant coated platelets which is dependent on cyclophillin D activity. Additionally, FXR ligands are able to increase cGMP levels that promotes the activity of PKG and phosphorylation of VASP S239 and thereby suppresses platelet activation.
Figure 1 LXR and FXR ligands negatively regulate platelet function through inhibition of platelet signalling and formation of procoagulant coated platelets. Treatment of platelets with LXR ligands results in reduced tyrosine phosphorylation of key GPVI signalling molecules Syk, LAT and PLCγ2. An increase in the level of LXR–Syk and LXR–PLCγ2 interaction is also observed. Exposure to LXR ligands also renders platelets into a procoagulant state characterized by the exposure of phosphatidylserine and α-granule contents on the platelet surface, which is coupled with depolarization of the mitochondrial membrane potential, reduced calcium mobilization and down-regulation in the affinity of integrin αIIbβ3, ultimately resulting in the inhibition of platelet aggregation. Similarly, incubation of platelets with FXR ligands can lead to platelet swelling and conversion to procoagulant coated platelets which is dependent on cyclophillin D activity. Additionally, FXR ligands are able to increase cGMP levels that promotes the activity of PKG and phosphorylation of VASP S239 and thereby suppresses platelet activation.CC BY · PubMed Central
Figure 2 Non-genomic regulation of platelets by PPAR ligands. PPARα ligands, fenofibrate or simvastatin and PPARβ/δ ligands, GW0742 and L-165041 cause a reduction in intracellular calcium mobilization and platelet activation. This inhibition was found to be mediated by augmented levels of cAMP and attenuation of PKCα through its interaction with PPARα or PPARβ/δ, which limits its availability to facilitate signalling downstream of PKCα. Treatment with PPARγ ligands inhibits platelet activation to collagen through an inhibition in phosphorylation of Syk and LAT that mediate signalling initiated by the collagen receptor GPVI. Negative regulation of integrin αIIbβ3 outside-in signalling was observed as an outcome of up-regulation of PKA activity and inhibition in phosphorylation of β3 and subsequent downstream signalling molecules—Syk, PLCγ2, PKC substrates, FAK and PI3K substrates.
Figure 2 Non-genomic regulation of platelets by PPAR ligands. PPARα ligands, fenofibrate or simvastatin and PPARβ/δ ligands, GW0742 and L-165041 cause a reduction in intracellular calcium mobilization and platelet activation. This inhibition was found to be mediated by augmented levels of cAMP and attenuation of PKCα through its interaction with PPARα or PPARβ/δ, which limits its availability to facilitate signalling downstream of PKCα. Treatment with PPARγ ligands inhibits platelet activation to collagen through an inhibition in phosphorylation of Syk and LAT that mediate signalling initiated by the collagen receptor GPVI. Negative regulation of integrin αIIbβ3 outside-in signalling was observed as an outcome of up-regulation of PKA activity and inhibition in phosphorylation of β3 and subsequent downstream signalling molecules—Syk, PLCγ2, PKC substrates, FAK and PI3K substrates.CC BY · PubMed Central
Figure 3 Inhibition of platelet function by RAR and RXR ligands is mediated through Arp2/3- and Gq-induced Rac activation and up-regulation of PKA activity, respectively. RAR ligand atRA disrupts the RARα–Arp2/3 interaction resulting in an inhibition of cytoskeletal rearrangements and platelet spreading. RXR ligands, 9cRA and methoprene acid inhibit platelet activation to a range of platelet agonists that include GPCR agonists (ADP, U46619 or thrombin) and GPVI agonists (collagen or CRP-XL). Interaction of RXR with Gq and subsequent negative regulation of Rac activation is one of the probable explanations for the reduction in GPCR-mediated platelet activation. These ligands have also been shown to up-regulate PKA activity in a cAMP- and NFκβ-dependent manner providing a more generalized mechanism of inhibition.
Figure 3 Inhibition of platelet function by RAR and RXR ligands is mediated through Arp2/3- and Gq-induced Rac activation and up-regulation of PKA activity, respectively. RAR ligand atRA disrupts the RARα–Arp2/3 interaction resulting in an inhibition of cytoskeletal rearrangements and platelet spreading. RXR ligands, 9cRA and methoprene acid inhibit platelet activation to a range of platelet agonists that include GPCR agonists (ADP, U46619 or thrombin) and GPVI agonists (collagen or CRP-XL). Interaction of RXR with Gq and subsequent negative regulation of Rac activation is one of the probable explanations for the reduction in GPCR-mediated platelet activation. These ligands have also been shown to up-regulate PKA activity in a cAMP- and NFκβ-dependent manner providing a more generalized mechanism of inhibition.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 107 references

Research works printed but not linked: 1

  1. Unsworth, 2017, PPARgamma agonists negatively regulate alphaIIbbeta3 integrin outside-in signalling and platelet function through upregulation of protein kinase A activity, J Thromb Haemost, 15, 356, 10.1111/jth.13578 · DOI

Cited by

See all 58

Metadata

Authors
Unsworth, A. J., Flora, G. D., & Gibbins, J. M.
Affiliations
School of Biological Sciences, Institute of Cardiovascular and Metabolic Research, Harborne Building, Whiteknights, Reading RG6 6AS, Berkshire, UK
Corresponding author
Gibbins, Jonathan M
Venue
Cardiovascular Research
Published
2018-02-14
Volume
114
Issue
5
Pages
645-655
ISSN
  • 0008-6363 (ISSN-L)
  • 1755-3245
OpenAlex
W2786404210
Cited by
54
References
108
Citations by year
2026: 6 · 2025: 8 · 2024: 3 · 2023: 10 · 2022: 5 · 2021: 6 · 2020: 5 · 2019: 7 · 2018: 3
FWCI
0.87
Type
journal article
Language
en
Open access
Locations
  • Cardiovascular Research (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • CentAUR (University of Reading) (acceptedVersion)
  • e-space (Manchester Metropolitan University) (acceptedVersion)
  • Figshare (submittedVersion, cc-by)
Funders
  • British Heart Foundation (RG/15/2/31224)
  • Felix Scholarship
Topics
  • Health Sciences › Medicine › Hematology › Platelet Disorders and Treatments
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nuclear Receptors and Signaling
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
Keywords
nuclear receptors, non-genomic signaling, platelets, anucleate cells, antiplatelet activity, ion channel function, intracellular calcium, second messengers
MeSH terms
Animals, Blood Platelets, Fibrinolytic Agents, Humans, Ligands, Platelet Aggregation Inhibitors, Protein Binding, Thrombosis, Signal Transduction, Receptors, Cytoplasmic and Nuclear

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Non-genomic effects of nuclear receptors: insights from the anucleate platelet. https://app.cochat.ai/papers/10.1093/cvr/cvy044
The paper
Unsworth, A. J., Flora, G. D., & Gibbins, J. M. (2018). Non-genomic effects of nuclear receptors: insights from the anucleate platelet. Cardiovascular Research. https://doi.org/10.1093/cvr/cvy044

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.